Health News Releases

  • Today December 20
April 29, 2019 09:45
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA
April 25, 2019 17:10
USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations
Aptorum Group Limited (Nasdaq: APM), Aeneas Capital Limited, and A*ccelerate Technologies Pte Ltd, the enterprise office of the Agency for Science, Technology and Research (A*STAR), have signed a USD$
April 24, 2019 18:05
Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019
Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet m
April 24, 2019 17:30
Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™
Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pha
April 24, 2019 17:30
Aptorum Group establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and unmet Diseases
Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and
April 23, 2019 13:50
Infraredx, a Nipro Company, Announces FDA Approval of Expanded Label Claim for the Makoto™ Intravascular Imaging System
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FD
April 23, 2019 00:00
Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer
Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
April 19, 2019 13:30
KCI Files Registration Statement for Proposed Initial Public Offering
Acelity announced today that its affiliate, KCI Holdings, Inc. (“KCI”), filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”), relating to a proposed init
April 17, 2019 18:00
Financial year 2018: Boehringer Ingelheim grows and invests
The research-driven pharmaceutical company Boehringer Ingelheim ended 2018 with net sales of 17.5 billion euros. Adjusted for currency effects, as well as one-off effects due to the asset swap with Sa
April 17, 2019 16:55
Acelity L.P. Inc. Announces New Senior Leadership Appointments
Acelity today announced Gaurav Agarwal, Chief Commercial Officer, has been promoted to the position of President and Chief Operating Officer. Additionally, Rohit Kashyap, President of the Americas, ha
April 17, 2019 13:10
CORRECTING and REPLACING SpeeDx and Cepheid Announce Test Partnership
First sentence, seventh paragraph of release dated April 16, 2019 should read: “Currently, there is no FDA-cleared molecular diagnostic test for the combined detection of M. genitalium and macrolide r
April 17, 2019 11:30
New Study Investigates Cerebral Oxygenation Normative Values Using Masimo O3® Regional Oximetry
Masimo (NASDAQ: MASI) announced today the findings of a study, recently published in Anaesthesia and Intensive Care, in which researchers at Austin Hospital in Melbourne, Australia sought to measure c
April 17, 2019 08:00
French Biotech CellVax is Now Able to Propose Preclinical Studies in Large Animals
Thanks to this strategic partnership, CellVax can now respond to the strong demand for optimal selection of models that represent the human disease best and is able to offer preclinical studies in lar
April 15, 2019 16:40
Independent large real-world study comparing NOACs in AF-patients
The results from an independent retrospective comparative study, published in January 2019 in the American Journal of Medicine, showed that dabigatran was associated with a more favourable benefit-har
April 15, 2019 16:35
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
Boehringer Ingelheim has acquired a minority stake in SoundTalks NV, a Belgian company. SoundTalks NV has developed a digital monitoring tool that seeks to improve the healthcare of pigs and helps far
April 15, 2019 09:45
New post-hoc analysis of EMPA-REG OUTCOME® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced results from a new cost-effectiveness analysis of the EMPA-REG OUTCOME® trial in a subgroup of 2,250 people with type 2 diabet
April 12, 2019 10:40
ResMed Introduces AirFit P30i, Its First Top-of-Head-Connected Nasal Pillows CPAP Mask
ResMed (NYSE: RMD, ASX: RMD) today introduced its second top-of-head-connected CPAP mask for treating sleep apnea, a new nasal pillows option, AirFit P30i. The mask’s “tube-up” connection, also fea
April 10, 2019 14:10
22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today
April 10, 2019 11:15
Alcon Debuts as Independent, Publicly Traded Company
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced its debut as an independent, publicly traded company and the completion of its separation from Novarti
April 09, 2019 17:25
Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine
Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’. Equine lameness is truly
April 05, 2019 10:40
Graminex L.L.C. Receives NNHPD Health Canada Approval for PollenBerry®
Graminex® L.L.C., producer of Graminex® Non-Solvent Flower Pollen Extracts™, receives Health Canada Approval under the Natural and Non-prescription Health Products Directorate (NNHPD) for its PollenBe
April 02, 2019 13:10
Terns Pharmaceuticals to Present Preclinical Data on Two Lead Programs at the European Association for the Study of the Liver (EASL) Annual Meeting 2019
Terns Pharmaceuticals, Inc. today announced presentation of preclinical data on its two lead programs at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the
April 01, 2019 12:00
Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regime
April 01, 2019 11:40
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD’s innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will employ this
March 28, 2019 18:00
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced initial results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world evidence study that show that empa
25 per page50 per page75 per page100 per page